BioMedNewsBreaks – DarioHealth Corp. (NASDAQ: DRIO) Announces New VP of Broker and Consultant Partnerships

DarioHealth (NASDAQ: DRIO), a pioneer in the global digital therapeutics market, has appointed Claudia Rimerman Kraut in the newly created role of vice president of broker and consultant partnerships. Kraut comes to her new responsibilities with impressive senior-management experience at Omada Health, American Well, AIG, United Healthcare and Humana. Kraut will lead Dario’s benefit consultant and alliance outreach and be a senior member of DRIO’s employer sales team. Kraut boasts a work record with a unique and notable combination of benefits, partnerships and digital health experience, most recently serving as director of alliances at Omada Health. “We believe that Claudia’s deep expertise and relationships in healthcare and digital therapeutics will strengthen our commercial team and positions us well to accelerate our growth in 2021 and beyond,” DarioHealth president and general manager of North America Rick Anderson stated in the press release. “As demonstrated by our recent announcement of customers won through benefit consultants, we believe relationships with benefits consultancies are a meaningful driver of our long-term growth.  We have had early success working with benefit consultants and we believe that Claudia will help us accelerate and expand our opportunities. We are pleased that someone with Claudia’s record of achievements has joined Dario to lead our broker and consultant relationships.”

To view the full press release, visit https://ibn.fm/EBqEB

About DarioHealth Corp.

DarioHealth is a leading global, digital-therapeutics company revolutionizing how people with chronic conditions manage their health. By delivering evidence-based interventions driven by connected devices, data, high-quality software and coaching, the company makes the right thing to do the easy thing to do. The company’s cross-functional team operates at the intersection of life sciences, behavioral science and software technology. Dario offers one of the highest-rated diabetes and hypertension solutions on the market; its highly engaging, user-centric MyDario(TM) mobile app is used regularly by tens of thousands of consumers worldwide. The company is rapidly expanding into new chronic conditions and geographic markets, using a performance-based approach to improve its users’ health. For more information about the company, please visit www.DarioHealth.com.

NOTE TO INVESTORS: The latest news and updates relating to DRIO are available in the company’s newsroom at http://ibn.fm/DRIO

About BioMedWire

BioMedWire (BMW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) BioMedNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. BMW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information please visit https://www.biomedwire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.biomedwire.com
415.949.5050 Office
Editor@BioMedWire.com

BioMedWire is part of the InvestorBrandNetwork

Chris@BMW

Share
Published by
Chris@BMW

Recent Posts

BioMedNewsBreaks — NextPlat Corp. (NASDAQ: NXPL, NXPLW) to Announce Q3 2025 Financial Results on Nov. 13 

NextPlat (NASDAQ: NXPL, NXPLW), a global consumer products and services company providing healthcare and technology…

2 days ago

BioMedNewsBreaks – Oncotelic Therapeutics, Inc. (OTCQB: OTLC) to Present Sapu003 Data at 2025 San Antonio Breast Cancer Symposium

Oncotelic Therapeutics (OTCQB: OTLC) a biopharmaceutical company advancing transformative cancer therapies through its PDAOAI platform…

5 days ago

BioMedNewsBreaks — HeartBeam Inc. (NASDAQ: BEAT) Schedules Third Quarter 2025 Conference Call for Nov. 13 

HeartBeam (NASDAQ: BEAT), a medical technology company transforming cardiac care through personalized insights, will hold…

6 days ago

BioMedNewsBreaks — Oncotelic Therapeutics, Inc. (OTCQB: OTLC) Featured in NetworkNewsWire Editorial on Nanomedicine Advances 

Oncotelic Therapeutics (OTCQB: OTLC) announced its inclusion in a NetworkNewsWire (“NNW”) editorial titled “Nanomedicine Innovations…

6 days ago

BioMedNewsBreaks – NextPlat Corp (NASDAQ: NXPL, NXPLW) Granted 180-Day Nasdaq Extension to Regain Minimum Bid Price Compliance

NextPlat (NASDAQ: NXPL, NXPLW), a global consumer products and services company providing healthcare and technology…

7 days ago

BioMedNewsBreaks — Nutriband Inc. (NASDAQ: NTRB) Receives FDA Meeting Feedback Advancing AVERSA(TM) Fentanyl Toward 505(b)(2) NDA Submission 

Nutriband (NASDAQ: NTRB), a developer of prescription transdermal pharmaceutical products, today announced it has received…

1 week ago